Allergan, an ABBVie company, today announced that the U.S. Food and Drug Administration has approved BOTOX ® for the treatment of detrusor overactivity associated with a neurologic condition in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. Neurogenic detrusor overactivity occurs when the spinal cord and bladder are not able to …
– Allergan, an ABBVie (NYSE: ABBV) company, today announced that the U.S. Food and Drug Administration (FDA) has approved BOTOX ® for the treatment of detrusor (bladder muscle) overactivity associated with a neurologic condition in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication.
First approved by the FDA in 1989 for 2 rare eye muscle disorders, onabotulinumtoxinA (Botox; Allergan) was the world’s first approved botulinum toxin type A treatment.